Eupraxia Pharmaceuticals Inc. EPRX
Eupraxia Pharmaceuticals Inc. (Nasdaq: EPRX) is a GI/hepatology drug developer. Its lead program, EP-104GI, is in Phase 2 for Eosinophilic esophagitis (EoE). Its next catalyst on record is EP-104GI: Interim analysis of Phase 2b portion of RESOLVE (first 60 patients at 6 months) (December 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EP-104GI — Interim analysis of Phase 2b portion of RESOLVE (first 60 patients at 6 months) (December 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EP-104GI (RESOLVE Phase 1b/2a and Phase 2b) | Eosinophilic esophagitis | small molecule | Phase 2 |
| EP-104IAR (SPRINGBOARD Phase 2 complete; Phase 3 PROMENADE planned) | Knee osteoarthritis pain | small molecule | Phase 2 |
| EP-105 | Post-surgical pain | small molecule | Pre-clinical |
| EP-201 | Post-surgical site infections | small molecule | Pre-clinical |
Recent results and decisions
- Nov 4, 2025met Phase 2b SPRINGBOARD met its primary endpoint and three of four secondary endpoints.
The trial met its primary endpoint and three of the four secondary endpoints.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.